Turn Therapeutics Inc. (TTRX) intrinsic value & 10-year financials
Turn Therapeutics Inc. (TTRX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.57
- Market cap
- $293.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -3124.1%
- Free cash flow (FY2025)
- —
TTRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$3.2M | -$0.12 | — | — | -6545.2% |
| FY2024 | — | -$1.8M | -$0.07 | — | — | 297.0% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Turn Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Turn Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -31.2% ROIC.
Turn Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Turn Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.